Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

https://ift.tt/N5FdVen

 

from Sanofi - Aventis Groupe https://ift.tt/3RdVSBj
via IFTTT

" May good health envelop you, spurring a quick recovery. .. "

from health care https://ift.tt/TJ9d7sm
via IFTTT https://ift.tt/bVKUNc4